AMD-070 hydrochloride, also known as Mavorixafor, is primarily used in the treatment of WHIM syndrome, a rare genetic disorder that affects the immune system. It works by blocking the CXCR4 receptor, which helps to mobilize white blood cells from the bone marrow into the bloodstream, thereby improving the immune response. This makes it particularly effective in reducing the frequency of infections and improving overall immune function in patients with WHIM syndrome. Additionally, Mavorixafor is being investigated for its potential use in enhancing the effectiveness of stem cell transplants and in the treatment of certain types of cancer, where it may help to mobilize cancer-fighting immune cells. Its ability to modulate the immune system also opens up possibilities for its use in other conditions where immune cell trafficking is a factor.